In 2022, the FDA issued a specific safety communication about dental problems associated with sublingual (dissolve-under-the-tongue) buprenorphine — worth understanding in detail, not just as a side note.
What the FDA found: Reports of dental problems — including cavities, tooth decay, oral infections, and tooth loss — in patients taking sublingual buprenorphine, including in people with no prior history of dental problems.
Why this happens: The exact mechanism isn’t fully established, but it’s thought to relate to the acidity of the dissolving medication and reduced saliva production, both of which can affect tooth enamel and oral bacteria over time with repeated daily exposure.
This is not a reason to stop treatment: The FDA’s communication explicitly emphasizes that the benefits of buprenorphine treatment continue to outweigh this risk, and patients should not stop taking their medication without talking to their provider first — this is a “manage the risk,” not a “stop the medication,” warning.
Practical steps that may help:
- Rinsing your mouth with water after the medication has fully dissolved (not before, since swishing early can reduce absorption)
- Waiting a period of time after dosing before brushing your teeth (brushing immediately after acid exposure can worsen enamel wear)
- Regular dental checkups, and mentioning your buprenorphine treatment to your dentist so they can watch for this specifically
- Injectable formulations (Sublocade, Brixadi) avoid this issue entirely, since they don’t involve daily oral dissolution — worth discussing as an option if dental problems become significant [link to injectable formulations article]
Medically reviewed by [pending]. Source: FDA Drug Safety Communication, January 2022.